1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable!

Dainippon Sumitomo (DSP) is one of those Japanese pharma companies which has changed its orbit by successful US launch of Latuda (Lurasidone, dopamine-2, serotonin-2 and serotonin-7 receptors agonist schizophrenia/bipolar disorder) in the last two years. But DSP’s expectation to generate $650m by FY2017 from its lead compound BBI-608 from mCRC is way unachievable. Pipeline Cancer Stem Cell Inhibitors- from OncoMed/Celgene (OMP-21M18, OMP-52M51) And Bionomics (BNC-101) also need a close watch. On M & A front (Table 11), DSP’s R & D collaboration with Edison pharma for EP-743 to target mitochondrial disease, with Healios for iPS cell technology demonstrates its interest for developing first in class drug to target niche market, but they do not fill the gap which it needs to fulfill its FY2017 MTP targets.

Due to that, no possibility should be ruled out for DSP to do some M & A for late stage compound in oncology space or in CNS/Respiratory space. BBI-608 Optimism Is Too High – Lead Indication -mCRC Opportunity, Pipeline CSC Inhibitors- From OncoMed/Celgene (OMP-21M18, OMP-52M51) And Bionomics (BNC-101) Need A Close Watch- LATUDA: US Blockbuster potential is unavoidable from genericized schizophrenia/bipolar disorder market, while opportunities in bipolar maintenance, MDD with mixed features and IM Depo formulation will be limited due to …………APTIOM AND OTHER PIPELINE CANDIDATES….

Table Of Contents

DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable!

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023

Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Schizophrenia for the seven majo ...

Schizophrenia - Epidemiology Forecast To 2023

Schizophrenia - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Schizophrenia - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Schizophrenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). ...

Parkinson%s Disease  - Epidemiology Forecast To 2023

Parkinson%s Disease  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Parkinson's Disease  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Parkinson's Disease  in seven major markets (US, France, Germany, Italy, Spain, ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.